Realisation off established targets at patients with diabetes type 2 at primary care setting.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25745

Enrollment

500

Registered

2005-09-13

Start date

2003-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes type II

Interventions

Two treatmentarms: Arm A: Addition of Rosiglitazone 8 mg od or Arm B: No addition of Rosiglitazone For each patient a regiment of treatment will be arranged concerning the glucose, bloodpressure

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes; 2. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Age 3 times upper limit; 8. Serum creatinine > 150 mmol/l; 9. Triglyceriden > 8 mmol/l.

Design outcomes

Primary

Measure	Time frame
The total amount of targets reached with treatment with Rosiglitazone compared with treatment with no Rosiglitazone.	—

Secondary

Measure	Time frame
The outcome of glitazone to the recent discovered riskfactors of diabetic patients.	—

Contacts

Public ContactM.A. Ree, van de

Diakonessenhuis Utrecht Internal Medicine P.O. Box 1002

MvdRee@diakonessenhuis.nl+31 (0)30 2566566

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)